CoImmune Announces Publication of Review of Clinical Development Program for CMN-001 in Metastatic Renal Cell Carcinoma

CoImmune, Inc., a clinical stage immuno-oncology company, has announced the publication of a review of their clinical development program for CMN-001 in metastatic renal cell carcinoma (mRCC). The review evaluates CMN-001, which is a dendritic cell-based immunotherapy electroporated with autologous tumor RNA. This groundbreaking treatment aims to redefine cancer treatment using cellular immunoth..